Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Nutrients ; 12(2)2020 Feb 14.
Artigo em Inglês | MEDLINE | ID: mdl-32075195

RESUMO

Celiac disease (CD) is an autoimmune enteropathy caused by an intolerance to gluten proteins. It has been hypothesized that probiotic bacteria may exert beneficial effects by modulating inflammatory processes and by sustaining peptide hydrolysis at the intestinal level. This study aims at evaluating the capacity of a probiotic mixture (two different strains of lactobacilli and three of bifidobacteria) to hydrolyze gluten peptides following simulated gastrointestinal digestion of gliadin (PT-gliadin). The capacity of bacterial hydrolysates to counteract the toxic effects of gliadin-derived peptides in Caco-2 cells was also assessed. The protein and peptide mixtures, untreated or proteolyzed with the probiotic preparation, were analyzed before and after each proteolytic step with different techniques (SDS-PAGE, reverse phase HPLC, filtration on different molecular cut-off membranes). These experiments demonstrated that PT-gliadin can be further digested by bacteria into lower molecular weight peptides. PT-gliadin, untreated or digested with the probiotics, was then used to evaluate oxidative stress, IL-6 cytokine production and expression of tight junctions' proteins-such as occludin and zonulin-in Caco-2 cells. PT-gliadin induced IL-6 production and modulation and redistribution of zonulin and occludin, while digestion with the probiotic strains reversed these effects. Our data indicate that this probiotic mixture may exert a protective role in CD.


Assuntos
Bifidobacterium , Gliadina/metabolismo , Gliadina/toxicidade , Lactobacillus , Probióticos/farmacologia , Hidrolisados de Proteína/farmacologia , Bifidobacterium/metabolismo , Células CACO-2 , Doença Celíaca/prevenção & controle , Doença Celíaca/terapia , Haptoglobinas/metabolismo , Humanos , Hidrólise , Interleucina-6/metabolismo , Lactobacillus/metabolismo , Peso Molecular , Ocludina/metabolismo , Estresse Oxidativo/efeitos dos fármacos , Probióticos/uso terapêutico , Precursores de Proteínas/metabolismo , Proteólise
2.
Adv Healthc Mater ; 7(12): e1701483, 2018 06.
Artigo em Inglês | MEDLINE | ID: mdl-29696813

RESUMO

Staphylococcus aureus is one of the most significant human pathogens that is frequently isolated in a wide range of superficial and systemic infections. The ability of S. aureus to invade and survive within host cells such as keratinocytes and host immune cells has been increasingly recognized as a potential factor in persistent infections and treatment failures. The incorporation of antibiotics into hyaluronan-cholesterol nanohydrogels represents a novel paradigm in the delivery of therapeutic agents against intracellular bacteria. The work presented herein shows that NHs quickly enter human keratinocytes and accumulate into lysosomes. When used for targeting intracellular S. aureus the antimicrobial activity of loaded levofloxacin is enhanced, possibly changing the antibiotic intracellular fate from cytosol to lysosome. Indeed, gentamicin, an antibiotic that predominantly accumulates in lysosomes, shows significant and equal antibacterial activity when entrapped into NHs. These results strongly suggest that lysosomal formulations may display preferential activity toward intracellular S. aureus, opening new avenues for the use of HA-based NHs for treatment of such skin infections.


Assuntos
Sistemas de Liberação de Medicamentos , Ácido Hialurônico , Hidrogéis , Queratinócitos/microbiologia , Levofloxacino , Nanoestruturas , Infecções Cutâneas Estafilocócicas/tratamento farmacológico , Staphylococcus aureus/crescimento & desenvolvimento , Humanos , Ácido Hialurônico/química , Ácido Hialurônico/farmacocinética , Ácido Hialurônico/farmacologia , Hidrogéis/química , Hidrogéis/farmacocinética , Hidrogéis/farmacologia , Queratinócitos/patologia , Levofloxacino/química , Levofloxacino/farmacocinética , Levofloxacino/farmacologia , Nanoestruturas/química , Nanoestruturas/uso terapêutico , Infecções Cutâneas Estafilocócicas/metabolismo , Infecções Cutâneas Estafilocócicas/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...